PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23714542-7	2013	Patients with EGFR mutations or ALK fusions should be treated with erlotinib or crizotinib, respectively, even in patients with tumor-related poor performance.	Erlotinib Hydrochloride	67-76	ALK receptor tyrosine kinase	Homo sapiens	32-35